Dr. Wang Discusses Crenolanib Plus Chemotherapy in AML

Eunice Wang, MD
Published: Tuesday, Jan 30, 2018



Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses the combination of crenolanib and cytarabine/anthracycline chemotherapy in patients with acute myeloid leukemia (AML).

A study presented at the 2017 ASH Annual Meeting evaluated the safety, feasibility, and efficacy of the novel FLT3 inhibitor crenolanib in combination with standard chemotherapy for patients with AML up to 60 years old who are FLT3-mutant. Patients were enrolled onto the study if they were newly diagnosed and untreated.

When looking at these patients, the results showed that the addition of crenolanib to chemotherapy was safe and well tolerated, Wang says. Of the patients evaluated, 29 (72%) achieved a complete response (CR) after 1 cycle of induction with cytarabine/anthracycline and crenolanib. Additionally, 3 patients achieved a CR after re-induction or after treatment with high-dose cytarabine or hematopoietic stem cell transplant. The adverse events were not significantly different than expected, said Wang.


Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses the combination of crenolanib and cytarabine/anthracycline chemotherapy in patients with acute myeloid leukemia (AML).

A study presented at the 2017 ASH Annual Meeting evaluated the safety, feasibility, and efficacy of the novel FLT3 inhibitor crenolanib in combination with standard chemotherapy for patients with AML up to 60 years old who are FLT3-mutant. Patients were enrolled onto the study if they were newly diagnosed and untreated.

When looking at these patients, the results showed that the addition of crenolanib to chemotherapy was safe and well tolerated, Wang says. Of the patients evaluated, 29 (72%) achieved a complete response (CR) after 1 cycle of induction with cytarabine/anthracycline and crenolanib. Additionally, 3 patients achieved a CR after re-induction or after treatment with high-dose cytarabine or hematopoietic stem cell transplant. The adverse events were not significantly different than expected, said Wang.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Highlights of ASH®: New Frontiers in the Management of AML Treatment: The Emerging Role of Targeted TherapiesMar 31, 20181.5
Publication Bottom Border
Border Publication
x